Skip to content

Comment on USA buys up world stock of remdesivirparent

Comments

None of these three points is the bottleneck. It's still easy to give someone an IV early on if they're in a high-risk group, it's not in that short supply, and at ~$2500 per treatment regimen it's not that expensive compared to an extended hospital stay.

The bottleneck is that it's only slightly effective.

AboutSource Built by g1lg1l

Hackerly is an independent reader for Hacker News, built on the public HN API. Not affiliated with Y Combinator.